Ensysce Capex To Revenue from 2010 to 2025
| ENSC Stock | USD 7.77 0.77 11.00% |
Capex To Revenue | First Reported 2010-12-31 | Previous Quarter 0.000001 | Current Value 0.000001 | Quarterly Volatility 0.00000004 |
Check Ensysce Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ensysce Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 373.2 K, Interest Income of 93.6 K or Interest Expense of 432.8 K, as well as many indicators such as Price To Sales Ratio of 17.63, Dividend Yield of 0.0411 or Days Sales Outstanding of 17.44. Ensysce financial statements analysis is a perfect complement when working with Ensysce Biosciences Valuation or Volatility modules.
Ensysce | Capex To Revenue |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:Check out the analysis of Ensysce Biosciences Correlation against competitors. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (29.10) | Revenue Per Share | Quarterly Revenue Growth (0.63) | Return On Assets | Return On Equity |
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.